2016年六大公司分手事件，安邦上榜

牵手一年零七个月后，安泰保险和同行哈门那公司在本周二放弃了它们价值350亿美元的合并计划。

两家保险商的合并在2016年的总统选举中受到指责。今年1月底，它们表示联邦法官和司法部站在了一起，不让它们合二为一。因此，安泰和哈门那同意叫停此事。按哈门那的流通在外股份计算，这项合并的价值为340亿美元。

预计安泰将向哈门那支付10亿美元税前“分手费”，这还不包括给律师和投行的服务费。

这次代价高昂的分手事件出现后，我们对去年未能成功的大规模合并案例进行了整理。

我们还按估算成本给这些案例排了序，这些数字由市场研究机构Dealogic提供，依据是相关公司的全面摊薄股份和债务。

6. KLA-Tencor和泛林集团：115亿美元

两家公司均来自半导体行业，2015年10月商定合并事宜。大约一年后，它们放弃了此项方案，原因是司法部以反垄断为由予以反对。司法部认为，这两家公司的合并将危及生产计算机芯片制造设备的对手企业。

5. 安邦保险和喜达屋：155亿美元

最初，中国的安邦保险和万豪国际在追求喜达屋的过程中势均力敌，但安邦在去年3月中旬把喜达屋争取到了自己这边。16天后，安邦保险突然收回了收购要约，说原因是“考虑到市场情况”。喜达屋和万豪国际最终敲定了价值136亿美元的合并方案。

4. 安泰保险和哈门那公司：350亿美元

去年10月安泰在提交给美国证监会的文件中称：“我们打算全力维护对哈门那的收购。”但华盛顿联邦法官表示此项合并有悖于反垄断规定后，安泰就不再坚持此事。

3. 哈里伯顿和贝克休斯：387亿美元

两大石油公司2014年11月决定合并。但出于对垄断的担心，司法部在2016年4月请求法院叫停此事，而欧盟监管部门预计也会表示反对。最终，哈里伯顿同意支付35亿美元的分手费。

2. Energy Transfer Equity和Williams：550亿美元

达科他州输油管道项目Dakota Access Pipeline承建商Energy Transfer Partners旗下的Energy Transfer Equity（ETE）去年6月份决定收回对输油管道运营商Williams的报价。ETE做出此项决定的原因是其法律顾问无法将此举纳入免税合并范畴，但ETE并未因此遭受损失。

1. 辉瑞和艾尔健：1600亿美元

辉瑞本打算把艾尔建的爱尔兰总部（爱尔兰税率较低）定为自己的新总部。但奥巴马政府对公司税收倒置的情况不是很满意。因此，美国财政部和国税局去年4月份颁布规定，极大地压缩了将总部迁至海外给企业带来的益处，从而终结了此项合并计划。辉瑞支付的分手费不多，只有1.50亿美元。（财富中文网）

译者：Charlie

After courting for a year and seven months, insurance companies Aetna and Humana axed their $35 billion merger plan Tuesday.

The two insurers, whose deal came under fire during the 2016 presidential elections, said that late in January, a federal judge had sided with the Department of Justice, blocking the proposed hookup. As a result Aetna and Humana agreed to call it quits on the deal, which would be valued at $34 billion based on Humana's shares outstanding only.

Aetna is expected to pay Humana $1 billion pretax as a result of the breakup—not including the fees expected to go to lawyers and bankers for their services.

In honor of that costly divorce, here's a list of companies in the last year that were prepared to form a massive partnership, only to break up.

The deals are ordered by their estimated cost, as calculated by Dealogic on the basis of their fully diluted shares and including debt.

6. KLA-Tencor and Lam Research: $11.5 billion

The two companies, both in the semiconductor industry, agreed to merge in October 2015. Roughly a year later, they called it quits when the Department of Justice opposed the deal on antitrust concerns. According to the DOJ, a combo would harm rival companies that build machines that put together computer chips.

5. Anbang Insurance and Starwood: $15.5 billion

At first, Chinese company Anbang was a mean opponent for Starwood's other suitor, Marriott International and even won over Starwood by mid-March of last year. Sixteen days later, Anbang abruptly rescinded its offer, citing "market considerations." Starwood and Marriott eventually agreed to merge in a $13.6 billion deal.

4. Aetna and Humana: $35 billion

"We plan to vigorously defend the Humana Acquisition," Aetna wrote in an October filing with the Securities and Exchange Commission. That defense ended when a federal judge in Washington, D.C. said the merger does violate antitrust rules.

3. Halliburton and Baker Hughes: $38.7 billion

The two oil giants decided to join forces in November 2014. But then the DOJ sued to block the merger on antitrust concerns in April 2016, while European Union regulators were expected to raise objections as well. Halliburton agreed to pay a $3.5 billion breakup fee as a result.

2. Energy Transfer Equity and Williams: $55 billion

Energy Transfer Equity, an affiliate of Dakota Access Pipeline-builder Energy Transfer Partners, decided to walk away from its offer for Williams in June. The decision was made after ETE's legal advisors couldn't declare the deal tax-free. ETE wasn't penalized for the breakup.

1. Pfizer and Allergan: $160 billion

Pfizer was ready to name Allergan's headquarters in Ireland (where taxes are lower) as its new home base. But the Obama administration wasn't too pleased with corporate inversions, so in April, the Treasury Department and the Internal Revenue Service unveiled regulations severely limiting the benefits of companies moving their headquarters abroad. That was the death knell for the merger. Pfizer paid a relatively tame $150 million for the breakup.